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ABSTRACT
HIV-1 Tat protein regulates transcription elongation
by binding to the 59 nt TAR RNA stem–loop structure
transcribed from the HIV-1 50 long terminal repeat (50-
LTR). This established Tat–TAR interaction was used
to investigate mRNA folding and RNA–protein inter-
actions during early transcription elongation from
the HIV-1 50-LTR. Employing a new site-specific
photo-cross-linking strategy to isolate transcription
elongation complexes at early steps of elongation,
we found that Tat interacts with HIV-1 transcripts
before the formation of full-length TAR (TAR59).
Analysis of RNA secondary structure by free energy
profiling and ribonuclease digestion indicated that
nascent transcripts folded into an alternative TAR
RNA structure (TAR31), which requires only 31 nt to
form and includes an analogous Tat-binding bulge
structure. Functionally, TAR31, similar to TAR59,
acts as a transcriptional terminator in vitro, and
mRNA expression from TAR31-deficient HIV-1 50-LTR
mutant promoters is significantly decreased. Our
results support a role for TAR31 in the control of
HIV-1 mRNA transcription and we propose that this
structure is important to stabilize the short early
transcripts before the transcription complex com-
mits for processive elongation. Overall, this study
demonstrates that RNA folding during HIV-1 tran-
scription is dynamic and that as the nascent RNA
chain grows during transcription, it folds into a
number of conformations that function to regulate
gene expression. Finally, our results provide a new
experimental strategy for studying mRNA conforma-
tion changes during transcription that can be applied
to investigate the folding and function of nascent
RNA structures transcribed from other promoters.
INTRODUCTION
RNA components of ribonucleoprotein complexes and
ribozymes fold into complex three-dimensional architecture.
The structural diversity of RNA includes a rich repertoire
of non-standard base pairing and backbone organization and
provides the basis for its biological role in macromolecular
assembly and catalysis (1). RNA folding is a dynamic process
governed by a number of factors, including charge, ionic
strength, nucleotide composition, solvents and RNA-binding
proteins. In addition, protein binding often leads to large-
scale rearrangements in RNA structure and induced RNA
structures contain non-standard base pairing, stacking and
distortion in grooves (2). The structural diversity of mRNA
suggests the potential for a relationship between varying
structure and resulting functional consequences. For example,
RNA folding during transcription is dynamic and RNA may
test a number of conformations as the nascent chain grows. In
turn, these conformations may vary in their regulatory func-
tions, leading to changes in the rate or efﬁciency of transcrip-
tion. Despite the undeniably important role of RNA in gene
regulation, it has been difﬁcult to acquire detailed structural
information regarding how RNA folding affects gene regula-
tion as the transcript is incrementally released from transcrip-
tion complexes. Thus, RNA structure and associated function
variations that occur during transcription elongation remain
an open question.
In eukaryotes, RNA polymerase II (RNA Pol II) can pause,
arrest, pass through terminator sequences or terminate tran-
scription after successfully initiating RNA synthesis. The
rate-limiting step in transcription elongation is the release
of RNA Pol II from stalled complexes (3). In the absence
of an inducer protein, RNA Pol II elongation complexes
pause 20–60 nt downstream from the promoter whereas
DNA- or RNA-binding activators release paused complexes
by recruiting or stimulating positive-acting transcription
elongation factors (4). One elegantly controlled eukaryotic
transcription elongation system involves the HIV-1 Tat pro-
tein, an RNA-binding protein that enhances elongation of
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elongation, Tat binds to the upper stem and bulge region of
trans-activation responsive (TAR) RNA, a highly structured
element in nascent viral RNA that forms within the 50 long
terminal repeat (50-LTR) region of HIV-1 during transcription
(6). Wei et al. (7) identiﬁed a protein termed Cyclin T1
(CycT1) that binds Tat activation domain. CycT1 together
with CDK9 forms the positive transcription elongation factor
b (P-TEFb) complex (8–10). The interaction of Tat activation
domain with a Ser/Thr kinase was ﬁrst suggested by copuri-
ﬁcation of TAK (Tat-associated kinase) with Tat-afﬁnity
chromatography (11–15). TAK also phosphorylated the
C-terminal domain (CTD) of RNA Pol II and this activity
was inhibited by a nucleoside analog, DRB (13). Further ana-
lysis of transcription elongation on HIV-1 LTR revealed that
TAK is a positive transcription elongation factor b, P-TEFb
(8–10). Tat cooperatively binds to TAR with P-TEFb
(16,17). The P-TEFb–Tat–TAR complex controls an early
step in transcription elongation that results in hyperphos-
phorylation of the CTD of RNA Pol II and increased pro-
cessivity of RNA Pol II (18). Recruitment of P-TEFb to
TAR has been proposed to be both necessary and sufﬁcient
for activation of transcription elongation from the HIV-1
LTR promoter (19).
Here, we devised a new experimental strategy to investig-
ate RNA-based control of human RNA Pol II-mediated tran-
scription elongation and establish the structure and function
of TAR during the earliest steps of transcription elongation.
Elongation complexes were isolated at different stages during
in vitro transcription and corresponding RNA–protein inter-
actions were analyzed by site-speciﬁc photo-cross-linking
experiments. Our results demonstrate that nascent RNA in
the elongation complex folds into an alternative TAR RNA
structure as soon as 31 nt are available for folding. This
31 nt TAR (TAR31) contains an inverted Tat-binding site
and interacts speciﬁcally with Tat in a bulge-dependent man-
ner. Furthermore, our studies show that TAR31 is biologic-
ally functional, acting as a termination signal and
promoting HIV-1 mRNA expression.
MATERIALS AND METHODS
In vitro transcription and cross-linking
The plasmid pWT2 was derived from the p10SLT plasmid
which contains the HIV-1 50-LTR (20). Plasmid pWT2 was
constructed by inserting a synthesized DNA fragment con-
taining a triplex target sequence (50-AAA AGA AAA GGG
GGG-30) between HindIII and NarI sites of plasmid
p10SLT. Oligodeoxyribonucleotides were synthesized on an
automated DNA/RNA synthesizer (ABI 392). Synthesis of
psoralen and biotin containing DNA probes, triplex formation
to the target sites in the plasmid DNA, photo-cross-linking
and puriﬁcation of RNA Pol II transcription complexes
were carried out as described previously (21).
HeLa cell nuclear extracts were prepared according to the
published procedures (22,23) with minor modiﬁcations (21).
Pre-initiation complexes (PICs) were formed by incubating
the immobilized DNA templates (200 ng) in a volume of
25 ml containing 12 ml of nuclear extract, 6 mM MgCl2
and 0.5 mg of poly(dA–dT) for 15 min at 30 C. PICs were
washed with 25 ml of washing buffer A [20 mM HEPES
(pH 7.9), 100 mM KCl, 20% (v/v) glycerol, 0.2 mM
EDTA, 0.5 mM DTT, 0.5 mM PMSF and 6 mM MgCl2]t o
remove unbound proteins. PICs were walked to position
U14 by incubation with 12.5 mM phosphocreatine, 20 mM
three NTPs (CTP, GTP and UTP), 20 mM dATP and
10 mCi [a-
32P]CTP (25 Ci/mmol, ICN; ﬁnal concentration:
160 mM) for 5 min at room temperature. Transcription
elongation complexes (TECs) stalled at U14 were washed
with 25 ml of wash buffer B (wash buffer A containing
0.05% NP-40 and 0.015% Sarkosyl) and twice with wash
buffer C (wash buffer A containing 0.05% NP-40). The
TECs stalled at U14 were walked stepwise along the DNA
by repeated incubation with different sets of three NTPs.
Unincorporated NTPs were removed by washing the immob-
ilized complexes with wash buffer C. To isolate RNA pro-
ducts from stalled TECs, 175 ml of stop solution (0.3 M
Tris–HCl, pH 7.4, 0.3 M sodium acetate, 0.5% SDS and
2 mM EDTA) was added. The mixture was extracted with
200 ml of phenol/chloroform/isoamyl alcohol (50:48:2) and
then with chloroform (200 ml). RNA transcripts were precip-
itated with ethanol and analyzed on 15% polyacrylamide–
7 M urea gels. 4-Thio UTP was incorporated in the ternary
complexes at U23 by stepwise walking of the elongation com-
plex as described above. After the TECs were stalled at the
desired position, they were washed three times with buffer
C (described above) and then incubated with 100 ng Tat pro-
tein in buffer D (20 mM HEPES, pH 7.9, 0.5 mM DTT,
100 mM KCl, 20% glycerol and 0.2 mM EDTA) for
10 min at room temperature. The mixture was UV irradiated
at 360 nm in a photochemical reactor for 15 min. The beads
were separated from the mixture by magnetic particle concen-
trator (Dynal, Great Neck, NY) and the complexes were ana-
lyzed on a 12% polyacrylamide gel. Cross-linking yields were
quantiﬁed using phosphorimaging (Molecular Dynamics).
RNA synthesis and RNA sequencing
TAR31 and TAR46 RNAs were prepared by in vitro tran-
scription (24,25). DNA was synthesized on an Applied
Biosystems ABI 392 DNA/RNA synthesizer or purchased
from Integrated DNA Technologies (IDT, IA). The template
strands encode the sequences for RNAs, with a T7 transcrip-
tion initiation site on the 30 end. The top strand is a short
piece of DNA complementary to the T7 initiation site (50-
TAATACGACTCACTATAG-30). The template strand of
DNA was annealed to an equimolar amount of top strand
DNA and transcription was carried out in transcription buffer
and 4 mM NTPs at 37 C for 2–4 h. For 20 or 100 ml reactions
containing 8 pmol template DNA, 40–60 U of T7 polymerase
(Promega) was used. To stop transcription reactions, an equal
volume of sample loading buffer was added to reactions.
RNA was puriﬁed on 20% acrylamide–8 M urea denaturing
gels and stored in DEPC water at  20 C.
Enzymatically transcribed RNAs were 50 dephosphorylated
by incubation with calf intestinal alkaline phophatase (Pro-
mega) for 1 h at 37 C in 50 mM Tris–HCl, pH 9.0, 1 mM
MgCl2, 0.1 mM ZnCl2 and 1 mM spermidine. RNAs were
puriﬁed by multiple extractions with Tris-saturated phenol
and one extraction with 24:1 chloroform/isoamyl alcohol
followed by ethanol precipitation. RNAs were 50-end-labeled
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32P]ATP (6000 Ci/mmol) (ICN) per 100 pmol
RNA by incubating with 16 U of T4 polynucleotide kinase
(New England Biolabs) in 70 mM Tris–HCl, pH 7.5, 10 mM
MgCl2 and 5 mM DTT. The RNAs were labeled at the 30 end
by ligation to cytidine-[50-
32P]bis-phosphate ([50-
32P]pCp)
using T4 RNA ligase. Reaction mixtures (50 ml) contained
250 pmol RNA, 65 mCi [50-
32P]pCp (3000 Ci/mmol;
NEN
TM, Boston, MA), and 40 U of T4 RNA ligase (New
England Biolabs) in a buffer containing 50 mM Tris–HCl
(pH 8.0), 3 mM DTT, 10 mM MgCl2, 25 mM NaCl, 50 mM
ATP, 25 mg/ml BSA and 10% (v/v) dimethyl sulfoxide. After
incubation at 4 C overnight, labeled RNAs were puriﬁed by
phenol–chloroform extraction and ethanol precipitation. 30-
and 50-end-labeled RNAs were gel puriﬁed on a denaturing
gel, visualized by autoradiography, eluted out of the gels,
and desalted on a reverse-phase cartridge.
RNA sequences were determined by base hydrolysis and
nuclease digestion. Alkaline hydrolysis of RNAs was carried
out in hydrolysis buffer for 8–12 min at 85 C. All ribonuc-
leases were purchased from Pharmacia. 50-o r3 0-End-labeled
RNA was incubated at room temperature with 0.05 U of 10 ml
RNase T1 (40 mM Tris–HCl, pH 8.0 and 1 mM EDTA) at
50 C for 2 min, or 0.5 U of 10 ml RNase U2 (30 mM sodium
citrate, pH 3.5, 1.5 mM EDTA and 0.3 mg/ml carrier tRNA) at
50 C for 5 min, 0.25 U of 10 ml RNase Bacillus cereus (Tris–
HCl, pH 8.0) for 5 min. Sequencing products were resolved
on 20% denaturing gels and visualized by phosphorimaging.
Structure probing of free RNA and RNA in TECs
50-end-labeled RNA was renatured in reaction buffer and
incubated at room temperature with 1 U of 10 ml RNase T1
(Tris–HCl, pH 8.0) for 5 min, 0.2–0.4 U for 10 ml RNase
V1 (5 mM Tris–HCl, pH 8.1, 60 mM NaCl and 5 mM
MgCl2) for 2 min, or 2.5–5 U for 10 ml nuclease S1 (5 mM
MES, pH 6.3, 120 mM NaCl and 5 mM MgCl2) for 2 min.
The reactions were quenched by adding sample loading buf-
fer. Fragments were analyzed on 20% polyacrylamide–7 M
urea gels.
TECs stalled at U46 were obtained by stepwise transcrip-
tion. The complexes were labeled with [a-
32P]UTP to obtain
30-end-labeled U46 TECs. After washing with wash buffer C
(three times), labeled complexes were re-suspended in diges-
tion reaction buffers and incubated at room temperature with
5 U of 50 ml RNase T1 (Tris–HCl, pH 8.0) for 5 min, 0.5–1 U
of 50 ml RNase V1 (5 mM Tris–HCl, pH 8.1, 60 mM NaCl
and 5 mM MgCl2) for 2 min, or 0.5–2 U of 50 ml RNase
B.cereus (Tris–HCl, pH 8.0) for 5 min. Reactions were
quenched with 165 ml of stop solution (0.3 M Tris–HCl, pH
8.0, 0.3 M NaOAc, 2 mM EDTA and 0.05% SDS). Labeled
RNAs were puriﬁed by phenol–chloroform extraction and
ethanol precipitation, and analyzed on 20% polyacrylamide–
7 M urea gels.
Electrophoretic mobility shift assays
RNA hairpins were transcribed in vitro and labeled as
described above. GST–Tat fusion proteins (wild-type and
D48 mutant) were expressed in Escherichia coli BL21(DE3)
and puriﬁed with the B-PER GST puriﬁcation kit (Pierce) fol-
lowing manufacturer’s instructions. RNA–protein-binding
reactions (20 ml) contained 50 fmol of 50-[
32P]-end labeled
RNA and 1 pmol of puriﬁed GST–Tat. Complex formation
was performed in TK buffer (50 mM Tris–HCl, pH 7.4, 20
mM KCl and 0.1% Triton X-100) and incubated at 4 C for
1.5 h. Complexes were separated from unbound RNA by elec-
trophoresis in non-denaturing 8% polyacrylamide gels con-
taining 0.1% Triton X-100. Gels were run at 4 C at 300 V
for 2 h and quantiﬁed by phosphorimaging.
DNA manipulations and plasmids
All new constructs were made from vector pBC12/HIV/
SEAP (renamed pwt/HIV/SEAP), which was a gift from Dr
Bryan R. Cullen (26). pm1/HIV/SEAP was made through
PCR ampliﬁcation of a 740 bp fragment between two BglII
restriction sites in pwt/HIV/SEAP. A mutant 30 end primer
was used to introduce nucleotide substitutions at positions 6
and 7 and a new base at position 7a (m1 mutations) in the
HIV1 50-LTR. To facilitate screening of mutant colonies, a
new MluI restriction site was introduced ﬂanking the BglII
site on the 50 end primer. The mutated PCR fragment was
cloned into the BglII sites of pwt/HIV/SEAP. pm2/HIV/
SEAP and pm3/HIV/SEAP clones were constructed via
PCR ampliﬁcation of a 3660 bp fragment between the two
AﬂII restriction sites of pm1/HIV/SEAP and pwt2/HIV/
SEAP, respectively. The 30 end primer introduces three new
bases and one base substitution at positions 53–56 of the
wild-type HIV-1 50-LTR. PCR fragments were cloned into
AﬂII sites of pm1/HIV/SEAP and pwt/HIV/SEAP to obtain
pm2/HIV/SEAP and pm3/HIV/SEAP, respectively. The com-
bined mutations in pm2/HIV/SEAP allow complete base pair-
ing of the lower stem of TAR59 and introduce a new XbaI
restriction site. pm3/HIV/SEAP only has mutations intro-
duced at positions 53–56 of TAR59. All primer sequences
are available upon request.
pCMVTatHA vector expresses Tat tagged at the C-
terminus with hemagglutinin (HA) from the CMV promoter
and was a gift from Dr B. Matija Peterlin (27). pSV-b-
galactosidase vector was purchased from Promega. Plasmid
concentrations were measured at 260 nm in a Shimatzu
UV-Visible 1601 spectrophotometer.
Cell culture and SEAP assays
Transcription efﬁciencies of wild-type and mutant HIV-1 50-
LTRs (m1, m2, m3) were compared with 293T cells in the
presence or absence of Tat. Cells were co-transfected with
pwt/HIV/SEAP, pm1/HIV/SEAP, pm2/HIV/SEAP, or pm3/
HIV/SEAP with or without pCMVTatHA. pSV-b-
galactosidase acted as a control for transfection efﬁciency
and 350 ng of each plasmid was used for transfection. Trans-
fection mixtures containing the indicated plasmids and 2 mlo f
cationic lipids (Lipofectamine 2000; Life Technologies) were
incubated in 100 ml OPTIMEM I buffer at room temperature
for 30 min. Transfection mixtures were added to 293T cells
(500 ml) plated on poly-D-lysine coated 24-well plates at a
ﬁnal concentration of 5 · 10
5 cell/ml. After incubating for
6ha t3 7  C, cells were cultured in DMEM/10% FBS at
37 C and 5% CO2. After 24 h, 20 ml of medium per sample
was collected and tested for SEcreted Alkaline Phosphatase
(SEAP) activity (Great EscAPe SEAP Fluorescence detection
kit; Clontech). Brieﬂy, dilution buffer was added to the col-
lected medium to a ﬁnal volume of 50 ml. Samples were
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alkaline phosphatase and, after equilibration at room temper-
ature, 97 ml of assay buffer and 3 ml of 1 mM 4-
methilumbelliferyl-phosphate (MUP) were added. After
incubation at room temperature for 1 h, samples were excited
at 360 nm and the emitted ﬂuorescence was read at 445 nm
on a Photon Technology International ﬂuorescence spectro-
photometer controlled by Felix software. For b-galactosidase
detection, cells were lysed with 200 ml of lysis buffer (M-
PER Mammalian Protein Extraction Reagent; Pierce) and
incubated at room temperature for 10 min with gentle shak-
ing. Two hundred microlitres of assay buffer (All-in-One
Mammalian b-galactosidase assay kit; Pierce) were added
to lysates, which were further incubated at 37 Ci n5 %
CO2 for 30 min. Reactions were quenched by the addition
of 150 ml of stop solution (Pierce). b-Galactosidase activities
were quantiﬁed by measuring OD at 405 nm in a Shimatzu
UV-Visible 1601 spectrophotometer. For protein quantiﬁca-
tion, 10 ml of lysate was added to 200 ml of Protein Assay
(Bio-Rad) in 800 mlo fH 2O and the OD was measured at
600 nm. Results are representative of at least six experiments.
SEAP activity was normalized for both b-galactosidase activ-
ity and protein concentration. A value of 100 was assigned to
the SEAP activity associated with the wild-type HIV-1 50-
LTR in the presence of Tat. SEAP values of remaining sam-
ples were calculated relative to the wild-type.
Total RNA isolation and mRNA quantification
The 293T cells were co-transfected with pwt/HIV/SEAP,
pm1/HIV/SEAP, pm2/HIV/SEAP, or pm3/HIV/SEAP with
or without pCMVTatHA. pSV-b-galactosidase acted as a
control for transfection efﬁciency and 350 ng of each plasmid
was used for transfection. Two sets of identical experiments
were arranged for each HIV-1 50-LTR construct. Twenty-four
hours post-transfection, the ﬁrst set of samples was assayed
for SEAP activity, b-galactosidase activity and protein con-
centration. The second set was tested for SEAP activity and
RNA transcription. Total RNA was isolated using the RNeasy
Kit (Qiagen). An average of 30 mg of total RNA per sample
was obtained. Five micrograms of total RNA per sample
were used in one-step RT/PCR to quantify SEAP mRNA
levels. Nucleotides 2623–2750 were ampliﬁed from the
HIV/SEAP vectors and corresponded to a non-coding insulin
region that ﬂanked the SEAP coding region. PCR ampliﬁca-
tion of nt 2103–2333 of b-galactosidase mRNA transcribed
from pSV-b-galactosidase controlled for mRNA recovery
and RT/PCR efﬁciencies. All primer sequences are available
upon request.
RNA samples were treated with one unit of RQ1 RNase
Free DNase (Promega) at 37 C for 30 min to remove all
traces of DNA contaminants. Reactions were quenched by
addition of stop solution (Promega) and heating samples at
65 C for 10 min. Each reaction contained 20 pmol of each
primer, 10 mCi of [a-
32P]dCTP (ICN), 1.5 ml of RT/Taq mix-
ture in RT/Taq buffer to a ﬁnal volume of 20 ml. Reverse
transcription was performed at 50 C for 30 min with the
denaturing step performed for 2 min at 94 C. Fifteen PCR
cycles were performed at 94 C for 30 s, 55 C for 30 s,
72 C for 1 min in a MiniCycler (MJ Research). Reactions
containing 5 U of Taq (Life Technologies), but not RT,
were performed as controls for DNA contamination. Reac-
tions (15 ml) were added to 15 mlo f2 · denaturing loading
buffer (80% formamide, 0.01% bromophenol blue and 0.8
mM EDTA), loaded on to 6% urea gel and run at 65 W for
2 h. Ampliﬁed fragments were visualized and quantiﬁed by
phosphorimaging.
RESULTS
RNA in early TECs photo-cross-links with Tat protein
We decided to probe mRNA folding and to study RNA–
protein interactions during transcription elongation at
different stages. Triplex DNA structure and psoralen photo-
chemistry were used to immobilize DNA templates and to
isolate homogeneous populations of RNA Pol II ternary com-
plexes stalled at speciﬁc sites (21,28). Figure 1A outlines our
experimental strategy: (i) insertion of a target sequence for
triple helix formation at a predetermined position in the
DNA template; (ii) restriction enzyme digestion to release
the triplex site upstream or downstream of the promoter
sequences; (iii) synthesis of a third strand containing a psor-
alen at its 50 end and a biotin at the 30 end; (iv) triplex forma-
tion between the DNA template and the third strand, followed
by UV irradiation (360 nm) to cross-link the complex;
(v) immobilization of cross-linked DNA templates on
streptavidin-conjugated magnetic beads followed by stepwise
in vitro transcription to incorporate site-speciﬁc photoactive
nucleosides; and (vi) incubation of stalled TECs with Tat fol-
lowed by UV irradiation to form the ﬁnal cross-link products.
Pre-initiation complexes were formed on immobilized
DNA templates and elongation was initiated by adding
dATP, UTP, CTP and GTP. Elongation complexes were
starved for ATP and stalled at U14, whereas further initiation
was inhibited by sarkosyl wash as described in Materials and
Methods. These stalled TECs underwent repeated incubation
with different sets of three NTPs, and accordingly, were
walked stepwise through transcription elongation (21,28).
Since RNA Pol II can start transcription at +1 and +2G
residues in the template DNA, two transcripts were observed
during walking experiments: one major product originating
from the +1 start site and a minor product resulting from
the +2 start site. Consistent with these observations, when
transcription was initiated with GpG dinucleotide triphos-
phate, a single RNA product was obtained (data not
shown). Viability of stalled complexes was conﬁrmed by add-
ing all four NTPs. This led to the production of runoff tran-
scripts of expected lengths and indicated that TEC complexes
were transcriptionally active (data not shown).
To investigate the interaction between Tat and TAR RNA,
UV inducible cross-linking reagent, 4-thiouridine (4-thioU),
was incorporated into RNA transcripts at position U23 during
stepwise transcription. We have previously shown that that 4-
thioU at U23 position in TAR RNA formed high efﬁciency
cross-links with Tat (25). The elongation complexes carrying
4-thioU were further walked to C61 by stepwise transcription.
The immobilized C61 TECs were 30-end-labeled with
[a-
32P]CTP in the last step of transcription, isolated and
washed thoroughly with transcription buffer. TECs contain-
ing labeled RNA were then incubated with Tat for 10 min
in TK buffer, and UV irradiated at 360 nm (see Materials
Nucleic Acids Research, 2006, Vol. 34, No. 15 4281and Methods). Products of the photoreaction were analyzed
by denaturing PAGE (12%). Irradiated RNA–protein com-
plexes yielded a band with electrophoretic mobility less
than that of RNA (Figure 1B, lane 4). This cross-linked pro-
duct was observed only when RNA was irradiated in the pres-
ence of Tat (Figure 1B, compare lanes 3 and 4). Irradiation
products analyzed by denaturing SDS–PAGE (15%) also
showed a Tat-dependent photoproduct that had a slower elec-
trophoretic mobility than TAR RNA (data not shown). Cross-
linked products were digested with Proteinase K, which
degrades cross-linked RNA–protein products but not cross-
linked RNA–RNA species (25,29). Proteinase K digestion
Biotin Psoralen
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Triplex Site
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Stepwise walking of Pol II
to incorporate 4-thioU at 23
+1
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RNA Pol II
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RNA Pol II
Tat
+1
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UV crosslinking
A
Figure 1. Specific Tat–TAR cross-link formation during transcription elongation. (A) Experimental design to incorporate a photoactive nucleoside into a nascent
RNA chain during transcription elongation. Plasmid pWT2 harboring an inserted target sequence for triplex formation was linearized with restriction enzymes.
A psoralen- and biotin-containing oligonucleotide was used to form triplex DNA. UV irradiation was then used to covalently cross-link psoralen to the template.
Psoralen-cross-linked template was immobilized on streptavidin-conjugated magnetic beads and non-cross-linked DNA was washed away with buffer. Stepwise
walking of RNA Pol II elongation complexes was used to incorporate the photoactive nucleoside 4-thioU into transcripts. Stalled TECs were incubated with Tat
and UV irradiated to form the final cross-link product. (B) Site-specific photo-cross-linking of Tat and TAR RNA in stalled ternary complexes. Stepwise RNA
Pol II walking was used to incorporate 4-thioU into TEC-associated transcripts at position 23. Tat was added to TECs stalled at C61 and UV irradiated (360 nm).
The gel shows RNA from non-irradiated TECs (lane 1); UV-irradiated TECs (lane 2); TECs in the presence of 100 ng Tat but not UV irradiated (lane 3); TECs in
the presence of Tat and UV irradiated (lane 4); TECs in the presence of Tat, UV irradiated, and digested with proteinase K at 37 C for 15 min (lane 5). RNA and
RNA–protein cross-link are labeled as RNA and R-P XL, respectively. M is a marker lane. (C) Photo-cross-linking of TAR RNA in TECs stalled at C61 with Tat
peptides. Lanes 1, 4 and 7 are non-irradiated control lanes with Tat peptides (amino acids 1–37), Tat peptide (amino acids 38–72), and full-length Tat,
respectively. The gel shows RNA from TECs incubated with Tat peptide (amino acids 1–37) and UV irradiated (lanes 2 and 3); TECs incubated with Tat peptide
(amino acids 38–72) and UV irradiated (lanes 5 and 6); TECs and full-length Tat and UV irradiated (lane 7). M is a marker lane (lane 8). (D) RNA–protein cross-
linking between Tat and the nascent RNA chain in the TECs stalled at different positions. Elongation complexes containing 4-thioU at position 23 were stalled at
G36, U42, U46, A51, C61 and C71. After incubating with Tat protein, photo-cross-linking reactions were performed and analyzed on denaturing gels as shown
above. RNA–protein cross-linking yields were determined by phosphorimaging.
4282 Nucleic Acids Research, 2006, Vol. 34, No. 15of the cross-linked products resulted in a loss of slower
mobility products and a gain in free RNA (Figure 1B, lane
5), ruling out the possibility that the observed shift in mobil-
ity was due to an RNA–RNA cross-link. Finally, the cross-
linked RNA–protein complex was stable at an alkaline pH
(9.2), high temperatures (85 C) and under denaturing condi-
tions (8 M urea and 2% SDS) (data not shown), suggesting
that a covalent bond was formed between nascent RNA and
Tat during the cross-linking reaction.
The speciﬁcity of RNA–Tat interactions was determined
by performing cross-linking reactions with two different Tat
peptides. TECs having 4-ThioU at position 23 and stalled at
C61 were incubated with the Tat transactivation domain [Tat
peptide (amino acids 1–37)] or the Tat RNA-binding domain
[Tat peptide (amino acids 38–72)] and UV irradiated. RNA in
the TECs did not cross-link with the transactivation domain
(Figure 1C, lanes 2 and 3), but efﬁciently cross-linked to
the RNA-binding domain to yield a slow mobility product
analogous to the shifted product seen with full-length Tat
(Figure 1C, compare lanes 5–6 to lane 8). These results sug-
gested that the RNA-binding domain of Tat binds to tran-
scripts produced from TECs stalled at C61. Competition
assays further established the speciﬁcity of the cross-linking
reaction between Tat and RNA from TECs stalled at C61.
In these experiments, Tat and unlabeled competitor RNA
were incubated with TECs stalled at C61 before performing
photo-cross-linking experiments. Wild-type TAR RNA
competed with TEC RNA more efﬁciently than bulgeless
TAR RNA to inhibit formation of cross-linked products
(data not shown), suggesting that TECs stalled at C61 contain
a functional TAR structure that speciﬁcally interacted with
Tat protein.
An alternative TAR RNA that has an inverted Tat-
binding site forms during transcription elongation
To determine the 30 end boundary of an RNA transcript that is
functional for Tat binding, we incorporated 4-thioU at posi-
tion 23, walked TECs to various positions, and performed
photo-cross-linking experiments with full-length Tat. TECs
stalled at G36, U42, U46, A51, C61 and C71 were analyzed
and the quantitative yields of resulting RNA–protein cross-
link products were measured. RNA from TECs stalled at
G36 did not cross-link to Tat, but all others formed RNA–
protein cross-links with efﬁciencies ranging from 20 to
55% (Figure 1D). These results indicate that RNA transcripts
from TECs stalled at U42 are sufﬁcient for Tat binding.
To verify the length of the transcript protected by stalled
TECS, RNA Pol II was walked to position A22 and stalled
TECs were divided into two fractions, with one subjected
to exhaustive RNase A digestion to hydrolyze the protruding
50 end of RNA transcripts. Both samples then were chased
with NTPs to walk TECs to U25, with [a-
32P]NTPs to
label transcripts (Figure 2A). RNA from each sample were
analyzed by PAGE and compared to an RNA marker
(Figure 2B). We observe that RNase A digested approxim-
ately six nt in TECs stalled at A22, indicating that no more
than 16 nt were protected by the TEC. These results were
in range of the 17–19 nt protected in a previous foot printing
analysis of arrested RNA Pol II elongation complexes (30). It
is known that there is some heterogeneity in the length of
transcript protected by different TEC and even <16 nt may
be covered by the TEC if RNase A could not digest more
than 6 bases owing to inefﬁcient enzymatic activity or steric
hindrance. In fact, during RNA structure probing experiments
(see below and Figure 3), ribonuclease T1 cleaved at posi-
tions G32, G33 and G34 when TECs were stalled at U46,
suggesting that only 12 nt of the RNA 30 end were protected
by the stalled elongation complexes.
If 12 nt were protected by TECs, only a 30 nt RNA tran-
script would be exposed for Tat recognition when TECs are
stalled at U42. However, a 30 nt transcript cannot fold into
a wild-type TAR conﬁguration. Similarly, RNA transcripts
in TECs stalled at A51 cannot adopt the wild-type TAR struc-
ture, but still cross-linked with Tat. To establish the structural
attributes of these shorter transcripts, an RNA folding pro-
gram (31) was used to search for RNA structures that could
form at shorter lengths. Figure 2C shows an interesting
stem–loop structure generated from this analysis that repres-
ents the most stable conformation of RNA transcripts con-
taining nt 1–31 (TAR31) and 1–46 (TAR46). This stem–
loop structure contained a 3 nt bulge (UCU) and sequences
above and below the bulge (outlined in a box) that were iden-
tical to an inverted Tat-binding site in TAR RNA. These
structural features suggested that before wild-type TAR
formed, an inverted TAR structure with the capacity to
bind Tat formed in association with TECs stalled at U42,
U46 and A51.
To ascertain that the proposed inverted TAR RNA struc-
ture exists in early nascent transcripts, we carried out sec-
ondary structure probing experiments. TAR31 and TAR46
were synthesized by in vitro T7 transcription and 50-end-
labeled with
32P (see Materials and Methods). Secondary
structure probing of 50-end-labeled TAR31 and TAR46
RNA transcripts was performed by ribonuclease digestion
(Figure 3A) and compared with RNA from the TEC stalled
at U46 (Figure 3B). The RNA samples were partially diges-
ted with RNase T1, RNase V1 and nuclease S1. RNase T1
is speciﬁc for G residues in loops and single-stranded
regions, RNase V1 is speciﬁc for double-stranded RNA
regions, and nuclease S1 is speciﬁc for cleavage of single-
stranded RNA. RNase T1 cleaved at position G16 within
TAR31 and TAR46 (indicated by arrows), and nuclease
S1 cleaved at positions U13, U14, A15 and G16 (high-
lighted by vertical lines), which was consistent with the
existence of the UUAG capping loop in the structure of
TAR31 and TAR46. Additional cleavage by RNase T1 at
positions G32 and G34 of TAR46 (indicated by vertical
lines) suggested that the predicted single-stranded region
formed downstream of the inverted TAR structure. RNase
V1 cleavage was observed at the 50 and 30 ends of TAR31
and TAR46, indicating that a double-stranded stem structure
was formed from 50 and 30 end base pairing of the RNA
transcript. Although cleavage at the UCU bulge of TAR31
was not clear in these experiments, RNase from B.cereus,
which is speciﬁc for single-stranded pyrimidine residues,
did cleave within the UCU region (Figure 3B). The UCU
region of TAR46 was also cleaved by nuclease S1 (high-
lighted with vertical lines), supporting the formation of an
inverted TAR structure. RNase U2 which cleaves at ApN
was also used in sequencing analysis. Taken altogether,
these cleavage experiments strongly support the existence
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Figure 2. Ribonuclease footprinting of nascent RNA in RNA Pol II TECs. (A) Experimental strategy of the RNase footprinting method. TECs were stalled at
position A22, subjected to exhaustive RNase A digestion, walked to U25 position and
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4284 Nucleic Acids Research, 2006, Vol. 34, No. 15of the proposed inverted TAR structure, both in isolated
RNA fragments and in TEC stalled at U46.
The speciﬁcity of binding of TAR31 to Tat was compared
with TAR59 by electrophoretic mobility shift assay (EMSA).
Short hairpin RNAs were transcribed in vitro,5 0-end-labeled
with
32P, and incubated with puriﬁed GST–Tat fusion protein
(see Materials and Methods). Incubation of TAR31 RNA
with GST–Tat resulted in a band with reduced mobility on
a native PAGE (Figure 4A). When increasing amounts of
unlabeled TAR59 were added to the binding reaction, the
shifted band disappeared gradually, showing that TAR59
competed with TAR31 for the binding of Tat in vitro
(Figure 4A). The addition of an unlabeled mutant TAR59
hairpin that cannot form the bulge structure required for
Tat binding did not affect the yield of TAR31-Tat binding.
Similar results were obtained using 50-end-labeled TAR59
with unlabeled TAR31 as a competitor. Results of competi-
tion experiments with both TAR31 and TAR59 are summar-
ized in Figure 4B. These results show that TAR31 and
TAR59 compete with each other for the binding of Tat, and
in both cases the interaction is speciﬁc for the bulge structure.
As a control, we used a GST-Tat D48 mutant, which does not
contain the RNA-binding site of Tat. Incubation of TAR31
and TAR59 with this mutant protein did not result in any shif-
ted band (Figure 4C), showing that the binding of Tat to
TAR31 or TAR59 is dependent on its RNA-binding motif.
These gel shift experiments conﬁrm that the TAR31 structure
makes speciﬁc interactions with Tat in a manner similar to
TAR59. These interactions are both dependent on the bulge
structure of TAR31 and the RNA-binding domain of Tat.
However, contrary to TAR59, TAR31 did not form a stable
ternary complex with Tat and Cyclin T1 (data not shown).
This is an expected result because TAR31 does not contain
a hexanucleotide loop which is essential for CycT1–Tat–
TAR ternary complex formation.
Alternative TAR structure can induce termination of
transcription elongation
In the absence of Tat, transcription elongation has been
shown to arrest after 58–61 nt are transcribed from the
HIV-1 50-LTR (32). The 58–61 nt RNA transcripts fold into
AB
Figure 3. Determination of alternative TAR structural elements by partial enzymatic digestion. (A) Secondary structure probing of 50-end-labeled TAR31 and
TAR46 RNA transcripts by digestion with ribonuclease T1, V1 and S1. Two concentrations of ribonuclease V1 and S1 were used. Lane C shows control RNA
without digestion. Lanes G and C + U are marker lanes. Lanes labeled OH
  contain an RNA alkaline hydrolysis ladder. Arrows indicate strong RNase T1
cleavage at position G16, and the vertical lines indicate loop and bulge regions uncovered by nuclease S1. (B) Structure probing of RNA in TECs stalled at U46
and comparison with free RNA. Lanes 1–4 contain 30-end-labeled TAR46 RNA from TECs and lanes 5–8 show 30-end-labeled free TAR46 RNA. Enzymes used
for RNA digestion are shown above the lane numbers. The lane labeled BC and U2 contain RNA treated with B.cereus RNase and with RNase U2, respectively.
The lane labeled OH
  contains an RNA alkaline hydrolysis ladder. Single-stranded regions are marked with vertical lines. Arrows indicate strong cleavage
bands.
Nucleic Acids Research, 2006, Vol. 34, No. 15 4285the TAR RNA structure and act as a termination signal.
To determine whether TAR31 was capable of terminating
transcription elongation such as TAR59, we stalled TECs
at position A22, chased with all four NTPs, and isolated
transcripts that were associated with TECs (beads) or ter-
mination products that were released by TECs during the
chase with NTPs (solution phase) (Figure 5A). Transcription
reactions were monitored at 6 s and 5 min time periods
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Figure 4. TAR31 competes with TAR59 for the binding of Tat in vitro. Binding of TAR31 and TAR59 to Tat was examined by electrophoretic mobility shift
assay (EMSA). (A) Competition experiments showing the binding of 50-end-labeled TAR31 short hairpin RNA to purified GST–Tat fusion protein in the
presence of increasing amounts (0- to 200-fold molar excess) of unlabeled competitor TAR59 wild-type (TAR59wt) or bulgeless mutant (TAR59mut). The lanes
labeled C are control lanes with RNA only. The RNA–protein complex is labeled RP. (B) Quantitative analysis of competition experiments with 50-end-labeled
TAR31 (light gray) and TAR59 (dark gray) in competition with unlabeled TAR59 and TAR31, respectively. Bands corresponding to RNA–Tat complex were
quantified from gels and lanes without competitor were assigned an arbitrary value of 1. Values are the means ± standard error of three independent experiments.
(C) Interaction between Tat and TAR31 requires the RNA-binding domain of Tat. Gel shows binding of 50-end-labeled TAR31 and TAR59 small hairpin RNAs
to wild-type GST-Tat or GST-Tat(D48) mutant that does not contain the RNA-binding domain.
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few different termination products, the two major ones having
a size of  46 and  60 nt (Figure 5B, lane 5). Quantiﬁcation
of band intensities in lane 5 revealed that only  21.8% TECs
produced the runoff products and the amount of terminated
transcripts containing 46 and 60 nt were 13.4 and 18.6%,
respectively. The 60 nt product corresponds to TAR59 and
is consistent with the capacity of full-length TAR to termin-
ate elongation. The presence of a 46 nt RNA transcript sug-
gests that TAR31 also acts as a transcription elongation
termination signal (see Discussion).
TAR31 is involved in the control of HIV-1 mRNA
transcription, but not in Tat transactivation
To determine whether TAR31 has a role in regulating HIV-1
50-LTR expression, the activity of a reporter gene under
TAR31-deﬁcient HIV-1 50-LTR promoters was tested. HIV-1
50-LTR mutants were constructed that did not contain the
TAR31-speciﬁc bulge but maintained the bulge–stem–loop
structure of TAR59 (see Figure 6 and Materials and Meth-
ods). Wild-type or mutant HIV-1 50-LTR constructs were
then inserted upstream of the SEAP reporter gene. The m1
construct had mutations (m1) introduced at positions 6–7
and a nucleotide insertion (7a) within the TAR31 stem that
replace the bulge structure of TAR31 with a double-stranded
stem, without changing the bulge and loop region that forms
the transcriptionally active portion of wild-type TAR59
(Figure 6, compare m1 TAR31 and m1 TAR59). However,
the m1 mutations caused a new internal bulge to form within
the lower stem structure of TAR59 (Figure 6, m1 TAR59).
Although this stem region is not necessary for Tat–TAR-
mediated transactivation (33), a second mutant construct
was made that contained the m1 mutations and secondary
compensatory mutations in the lower stem of TAR59 that
included three new bases and one base substitution between
positions 53–56 (Figure 6, m2 TAR59). This m2 mutant 50-
LTR retains an intact wild-type TAR59 stem structure but
lacks the bulged structure of TAR31. To verify that these
compensatory mutations did not affect TAR activity, a con-
trol construct was made that only had the m2 compensatory
mutations in the lower stem of TAR59 and allowed formation
of both the TAR31 bulge and TAR59 stem structures
(Figure 6, m3 TAR59).
Wild-type and mutant HIV-1 50-LTR-SEAP plasmids were
transfected into 293T cells with pSV-b-galactosidase as a
control for transfection efﬁciency. Co-transfections were per-
formed with or without pCMV-Tat-HA, which expresses a
functional Tat–hemagglutinin (HA) fusion protein. The
effects of the various HIV-1 50-LTR mutants were determined
both on the levels of SEAP mRNA expressed and SEAP pro-
tein produced. Each co-transfection was performed in duplic-
ate with SEAP, b-galactosidase activity and total protein
A
Beads
Chase with NTPs
Solution
- released RNA transcript
- termination by RNA structures
Beads
runoff products stalled
at +185 crosslink site
+1
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B Beads Solution
Figure 5. TAR31 acts as a transcription elongation termination signal. (A)
Experimental outline for analyzing transcription elongation termination.
A homogeneous population of TECs were stalled at A22 position and chased
with unlabeled NTPs. Beads and solution phases were separated and analyzed
on denaturing gels as described previously (21). Transcription reactions were
monitored at 6 s and 5 min time periods. (B) Analysis of transcription
products. Lane 2 shows transcripts from TECs stalled at position A22. Lanes 3
and 4 are transcripts from TECs chased with NTPs for 6 s and 5 min,
respectively. Lane 5 contains transcripts released from TECs into solution
during the 5 min chase with NTPs. Lane 6 is a marker lane. Two major
termination signals were observed around 46 nt (*) and 60 nt (&). Quantitative
analysis of band intensities in lane 5 shows that  21.8% TECs produced the
runoff products and the amount of terminated transcripts containing 46 and
60 nt were 13.4 and 18.6%, respectively.
Nucleic Acids Research, 2006, Vol. 34, No. 15 4287concentration assayed in one set of experiments, and SEAP
mRNA and total RNA levels measured in a mirroring set of
experiments. b-Galactosidase and total protein levels were
consistent among all transfections analyzed, suggesting that
the HIV-1 50-LTR mutants did not affect protein expression
in general (data not shown). The presence of Tat increased
the transcriptional activity from the wild-type HIV-1 pro-
moter, resulting in 10- to 20-fold increase in SEAP protein
levels. Mutants m1 and m2, which did not contain the bulged
structure of TAR31, showed a 50–60% reduction in Tat-
induced SEAP expression (Figure 7A). Mutant m3, which
was structurally wild-type for both TAR31 and TAR59,
showed SEAP levels comparable to wild-type HIV-1 pro-
moter. Total RNA isolated from cells transfected with
wild-type or mutant 50-LTRs was subjected to [a-
32P]dCTP
RT–PCR to quantify SEAP and b-galactosidase mRNA levels
(Figure 7A and B). b-Galactosidase mRNA was a control for
total RNA extracted from each sample. In the absence of the
TAR31 structure (m1 and m2 mutants), a 40–50% reduction
in SEAP mRNA levels was observed that was highly correl-
ative to the reduced SEAP expression observed with the m1
and m2 mutants (Figure 7A). The m3 mutant showed wild-
type mRNA levels, indicating that the reduction in mRNA
levels associated with the m1 and m2 mutants was speciﬁc
to the loss of the TAR31 structure. These experiments show
that the decreased SEAP expression observed when deleting
the TAR31 region stems from defects at the transcriptional
level and not from defects in translation.
TAR31 lacks a hexanucleotide loop structure and did not
form a ternary complex with Tat and Cyclin T1 in vitro
(data not shown), suggesting that Tat–TAR31 complexes
were not involved in CycT1–Tat–TAR59-mediated trans-
activation. We tested this hypothesis by measuring the relat-
ive levels of Tat transactivation for wild-type and mutant
50-LTR-SEAP constructs. Tat transactivation was established
by comparing SEAP protein expression and mRNA levels in
the presence and absence of Tat. The m1 and m2 mutants
exhibited levels of Tat transactivation that were only slightly
lower than wild-type TAR31-containing 50-LTR promoters
(Figure 7C), indicating that TAR31 did not have a role in
Tat transactivation. The basal activities of the mutant 50-
LTR promoters lacking TAR31 were lower compared to
TAR31-containing 50-LTRs, which raises the possibility
that TAR31-deﬁcient mRNA transcripts were less stable
than wild-type transcripts. Nuclear, non-mature TAR31-
deﬁcient mRNA may be degraded at a higher rate, or may
Figure 6. Structure of wild-type and mutant TAR RNAs used in this study. TAR31 and TAR59 represent alternative structures of wild-type HIV-1 LTR. m1
TAR31 and m1 TAR59 represent alternative structures of a mutant LTR with two base substitutions at positions 6 and 7 and a base insertion at position 7a,
preventing the formation of the TAR31 bulge without affecting the structure of TAR59 (mutated positions are shown in red). Mutant m2 contains the same
mutations as mutant m1, plus three new bases and one base substitution between positions 53 and 56, which restore the wild-type lower stem structure of TAR59.
Mutant m3 contains the same three new bases and one base substitution between positions 53 and 56 as mutant m2, but has wild-type nucleotides at positions 6
and 7 and does not affect the structures of TAR31 or TAR59.
4288 Nucleic Acids Research, 2006, Vol. 34, No. 15be exported from the nucleus at a lower frequency, increasing
their vulnerability to nucleases. Alternatively, cytoplasmic,
mature TAR31-deﬁcient mRNA may be targeted for degrada-
tion at a higher rate then wild-type TAR mRNA.
To address whether TAR31-deﬁcient mRNAs had defects
in export or were less stable in the cytoplasm, cells transfec-
ted with wild-type or mutant 50-LTR promoters were treated
with the general transcription inhibitor actinomycin D (1 mM)
24 h post-transfection. SEAP activity was used to evaluate
the half-life of mature mRNA in the cytoplasm since we
had already shown that SEAP protein levels correspond to
mRNA levels. After adding actinomycin D, media were
removed from cells at various time points and assayed for
SEAP activity. To rule out the possibility of SEAP protein
accumulation and/or degradation in the media, older media
were replaced with fresh media 20 min before taking aliquots
assayed for SEAP activity. SEAP activity decreased with
increased exposure time to actinomycin D for all wild-type
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Figure 7. In vivo functional studies of alternative TAR. TAR31-deficient mutant HIV-1 LTRs express lower RNA levels but do not affect Tat-mediated
transactivation, mRNA export or cytoplasmic mRNA degradation. (A) Levels of SEAP reporter protein and mRNA in 293T cells transfected with wild-type and
mutant HIV-1 50-LTR-SEAP constructs in the presence or absence of Tat (see text for details). SEAP values were corrected for protein concentration and
b-galactosidase activity to measure transfection efficiency. Expression levels were normalized to wild-type HIV-1 50-LTR expression levels of SEAP in the
presence of Tat, which was assigned a value of 100. Each set of experiments was repeated at least six times. mRNA was isolated from cells transfected with wild-
type and mutant HIV-1 50-LTR and quantified by RT–PCR (B). mRNA levels were normalized to mRNA levels detected from the wild-type HIV-1 50-LTR in the
presence of Tat, which was assigned a value of 100. Values were obtained from at least five different sets of experiments and normalized to b-galactosidase
mRNA levels to control for transfection efficiency. (B) Visualization of RNA levels transcribed from wild-type and mutant HIV-1 50-LTRs. A 128 nt region
downstream from the HIV-1 50-LTR promoter in wild-type and mutant HIV-1 50-LTR-SEAP plasmids and a 221 nt region of the b-galactosidase coding domain
in the b-galactosidase control vector were separately reverse transcribed and amplified. PCR products were labeled with [a-
32P]dCTP during the amplification
step and loaded on to a 6% denaturing urea gel. Lanes 1–4 show PCR products (WT, m1, m2 and m3, respectively) from cells not expressing Tat whereas
lanes 5–8 products were from cells expressing Tat. (C) Relative measure of Tat transactivation using the SEAP reporter gene assay and mRNA quantification
assays. Tat transactivation was calculated as the ratio of SEAP or mRNA levels in the presence of Tat and SEAP or mRNA levels in the absence of Tat, and
measured as described in Materials and Methods. (D) Rate of cytoplasmic mRNA degradation. Wild-type and mutant HIV-1 50-LTR-SEAP vectors were
transfected into 293T cells. At 24 h post-tranfection, media were replaced with fresh media containing 1 mM actinomycin D and cells were further incubated at
37 C for 1, 2, 4 or 7 h. At each indicated time, media were replaced with fresh actinomycin D-containing media; after 20 min, 20 ml aliquots were collected and
tested for SEAP activity as described in Materials and Methods. After 7 h all media were removed. Cells were washed with 1· PBS and lysed for b-galactosidase
detection and protein quantification as described in Materials and Methods.
Nucleic Acids Research, 2006, Vol. 34, No. 15 4289and mutant constructs tested. However, no signiﬁcant differ-
ences in SEAP activity were observed for any of the con-
structs tested at any one particular time point after the
addition of actinomycin D (Figure 7D). These results show
that the rates of cytoplasmic mRNA degradation for wild-
type and TAR31-deﬁcient mRNA were the same. These res-
ults also ruled out a function for TAR31 in either mRNA
export or stabilization of mature cytoplasmic mRNA. Taken
together, these experiments show that TAR31 has a role
in the control of HIV-1 mRNA expression during early
transcription.
DISCUSSION
In this study, we identiﬁed a novel RNA structure resembling
an inverted TAR that interacts speciﬁcally with Tat protein,
can terminate transcription in the absence of Tat, and is
important for the control of HIV-1 mRNA transcription.
This analysis demonstrates that during transcription elonga-
tion, mRNA transcripts fold into different conformations to
regulate gene expression. The success of the methodology
established here exempliﬁes how in vitro transcription and
cross-linking chemistry can be combined to study RNA
Pol II complexes at different stages of transcription. Further-
more, our site-speciﬁc photo-cross-linking experiments pro-
vided a window for capturing RNA–protein interactions
during speciﬁc steps of transcription, and Tat–TAR recogni-
tion served as a functional test to identify alternative TAR
RNA structures. An RNA folding program and structural
probing experiments then revealed the structural formation
of the inverted TAR.
The free energy of TAR31 and wild-type TAR59 folding
within RNA transcripts that varied in length was also calcu-
lated using the mfold program (31) (Figure 8). When RNA
transcripts available for folding were shorter than 50 nt,
RNA structures containing TAR31 had a lower free energy
than TAR59, suggesting that TAR31 predominates at early
stages of transcription elongation. For a 50 nt RNA transcript,
the free energy of the two structures was identical and we
would predict that both structures co-exist in equal ratio.
When an RNA transcript grows longer than 50 nt, the free
energy of TAR59 decreases dramatically, indicating that
TAR59 should be most predominant at these longer lengths.
The yields obtained from cross-linking experiments suppor-
ted the formation of these predicted RNA structures. If
TECs protect 12 nt of the RNA transcript, TECs stalled at
U46 and C71 would expose RNA transcripts containing 36
and 59 nt, respectively. Thirty six free nucleotides should
fold into TAR31 while 59 nt should favor TAR59 formation,
and both should provide stable Tat-interacting regions. Cor-
respondingly, the high yield of U46 and C71 cross-link pro-
ducts was indicative of stable formation of TAR31 and
TAR59, respectively. TECs stalled at U42 should form a
TAR31-like structure with a few nucleotides less than full-
length TAR31. TECs halted at C61 should expose 49 nt,
which most probably adopted TAR31 and TAR59 conforma-
tions since the difference in free energy values of both TAR
structures was not signiﬁcant (2 kcal/mol).
TECs stalled at A51, which expose 39 nt transcripts, pro-
duced the lowest yields of RNA–protein cross-links. Two
possibilities may explain this result. First, small differences
in the free energies (1.6 kcal/mol) of the TAR31 and
TAR59 conformations raises the possibility that the 39 nt
transcript co-existed in both conformations. In having such
a dynamic structure, 39 nt may not form a stable Tat-
interacting site, explaining the low yield of cross-link pro-
ducts. An alternative explanation stems from an elegant
study that showed the ﬁrst 44 nt of HIV-1 RNA folded into
an alternative structure called the HIV-1 pause hairpin (34).
This hairpin structure required only 39 nt to form a stable
structure. The free energy values for HIV-1 pause hairpin
formation and TAR31-containing structures were  12.6
and  12.7 kcal/mol, respectively, which suggested that
the pause hairpin and TAR31 co-existed when TECs were
stalled at A51. The pause hairpin structure does not contain
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Figure 8. Free energy of TAR31 and TAR59 structures in HIV-1 mRNA transcripts of different lengths. Graph shows the free energy values of TAR31 (closed
circles) and TAR59 (open squares) secondary structure formation with respect to transcript length (between 28 and 59 nt). See Discussion for details.
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Tat. Therefore, formation of this structure would decrease
Tat–TAR31 cross-link efﬁciency. These two explanations
for the lower cross-link yield with the A51 mutant are not
mutually exclusive. Collectively, these analyses strongly sug-
gest that TAR31 forms when the active center of the TEC
reaches U42, wild-type TAR RNA forms after 50 nt are
released, and intermediate, dynamic structures form when
median length RNA becomes free from TECs. When the
full-length TAR structure becomes available for Tat binding,
formation of the P-TEFb–Tat–TAR ternary complex should
shift the equilibrium towards the TAR59 structure and pre-
vent the formation of alternate structures.
The Tat–TAR31 cross-link and the EMSA experiments
suggest that Tat can bind to HIV-1 transcripts before
TAR59 formation. The in vivo mutant HIV-1 50-LTR analysis
also indicated that the TAR31 bulge was functionally import-
ant. In the SEAP assays, HIV-1 50-LTR mutants lacking the
bulge structure of TAR31 showed half the activity of pro-
moters containing the bulge, suggesting that TAR31 func-
tions at the level of transcription. The decreased mRNA
levels associated with TAR31-deﬁcient transcripts could
have been caused by defects in transcription initiation, Tat
transactivation, mRNA transport or transcript stability. How-
ever, TAR31 did not form a detectable complex with Cyclin
T1 and Tat transactivation was only slightly decreased when
TAR31 was mutated. These results suggested that TAR31
was not required for assembling P-TEFb/Tat/TAR com-
plexes, for Tat transactivation, or transcription initiation.
TAR31 was also not required for mRNA export or cytoplas-
mic mRNA stability since wild-type and TAR31-deﬁcient
cytoplasmic mRNAs degraded at similar rates. The exact
role of TAR31 remains an open question, but it is clear that
it is involved during early elongation step. We propose two
hypotheses for future work: (i) TAR31 structure is important
to stabilize the short early transcripts before the transcription
complex commits for processive elongation; and (ii) TAR
31 actively promotes transcription elongation in an as yet
unknown mechanism.
In conclusion, the study presented here shows that mRNA
folding during transcription can be a determinant for efﬁcient
gene expression. This study also revealed that RNA serves as
a dynamic receptor for varying RNA–protein interactions.
Finally, our new experimental strategy for studying mRNA
conformation changes during transcription can be applied to
investigate the folding and function of nascent RNA struc-
tures transcribed from other promoters.
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